The new federal disclosure rule gives employers a fuller view of how pharmacy benefit managers are paid, including arrangements that may affect drug costs or create conflicts of interest. The Trump administration finalized the regulation Thursday. Its central idea is straightforward: employers that sponsor health coverage should be able to see more of the money flowing between PBMs, drugmakers and other parties involved in prescription benefits.
PBMs sit between health plans, pharmacies and drug manufacturers. They can negotiate prices and rebates, process prescription claims, and help determine which medicines a plan covers and what patients pay at the pharmacy counter. Employers often rely on PBMs to manage these tasks, while the details of payment arrangements can be difficult for a plan sponsor to inspect. More disclosure could help employers understand how those arrangements affect the services they buy and the costs their plans bear.
Starting July 1, 2027, PBMs must report compensation from drugmakers, consulting firms and other entities. Disclosures will cover drug rebates, spread pricing and financial ties to brokers and consultants. Those categories matter because a PBM’s revenue can come from more than the fee an employer sees on an invoice. The rule is intended to make those sources more visible, giving employers information they could use when reviewing contracts or comparing services.
What the disclosures could show
Rebates are payments associated with drug purchases and negotiations between manufacturers and intermediaries. Their existence alone doesn’t reveal who ultimately benefits: the amount passed through to a health plan, the amount retained by a PBM, and the way a contract defines those payments can all affect the final picture. Reporting rebate information could help employers trace those flows, though it won’t by itself determine whether a particular arrangement lowers costs for patients or the plan.
Spread pricing describes a difference between what a plan is charged for a prescription and what a pharmacy is paid. When that difference is part of a PBM’s compensation, an employer may have difficulty assessing the total cost from a headline administrative fee alone. Disclosure could make the arrangement easier to identify and question. The practical value will depend on whether employers can interpret the data and connect it to the terms of their contracts.
Financial relationships with brokers and consultants add another layer. Those professionals may help employers choose benefits vendors or advise them on plan design, so information about payments and other ties can matter when an employer evaluates whose interests are being served. (And this is the part most people overlook.) A disclosure can reveal a relationship without proving that it changed anyone’s recommendation. Context and clear reporting will matter.
Broad reach, projected savings
Federal officials estimate the rule will cover more than 70 PBMs and 130,000 employers, with annual savings exceeding $800 million through lower drug costs. These are projections, not a guarantee that each employer will see lower spending. The savings estimate signals the administration’s expectation that greater visibility can improve purchasing decisions or contract oversight; the result will depend on how employers use the information and whether it leads to changes in their arrangements.
The disclosures could give employers access to extensive data that has been closely protected. That access could narrow an information gap between the firms administering prescription benefits and the organizations paying for them. Yet raw disclosure isn’t the same as useful transparency. Employers will need to understand what the figures cover, compare them with contract terms, and decide whether a payment arrangement is producing value for their plan.
This is more significant than it looks. A rule can change the questions employers are able to ask even before it changes the underlying prices or payment flows. If a plan sponsor can see more clearly how a PBM is compensated, it may be in a stronger position to scrutinize fees, rebates and pricing practices during contract discussions. Whether that pressure reaches patients’ out-of-pocket costs is a separate question.
Transparency has limits
Disclosure rules address an information problem, but they don’t automatically settle disputes about how prescription benefits should be structured. Similar systems typically rely on definitions, reporting standards and records that allow the parties to compare what was disclosed with what a contract requires. If the information arrives in a form that employers can’t readily interpret, the formal obligation may deliver less practical insight than its scope suggests.
There’s also a difference between knowing that money changed hands and knowing how that payment affected a drug’s net cost. Rebates, fees and other compensation can interact with benefit design and purchasing terms. A fuller report may give employers a better starting point for examining those relationships, but it won’t necessarily produce a simple answer about which party saved money on a particular prescription.
For employers, the work will likely be analytical as well as administrative: identify the relevant payments, compare them with the services provided, and decide what questions to take back to a PBM or adviser. If you’re working in this space, the quality of the reporting may matter as much as the breadth of the categories. More detail, properly organized. Without that, a large disclosure can still leave the central business question unresolved.
What comes next
The July 1, 2027 start date gives employers and PBMs a defined point to prepare for the reporting requirement. The immediate test will be whether disclosures make compensation easier to understand across different arrangements, rather than simply increasing the volume of information available. Employers will also need to determine how the reports fit into their existing reviews of benefit costs and vendor contracts.
That said, the rule’s projected savings should be treated as an estimate until employers can assess the data and see what decisions it supports. The regulation could make previously protected financial relationships more visible and sharpen scrutiny of how PBMs are paid. It can’t, on the facts provided here, establish what any one employer will save or how much patients’ costs will change. The disclosures will show more of the machinery; their effect will depend on what employers do with the view.